Ania Jastreboff, an obesity medicine physician scientist at Yale University School of Medicine/Yale School of Medicine, co-Director of the Yale Center for Weight Management and the lead author on the phase 2 study, said that the results were striking and concluded that Retatrutide holds promise for substantial weight reduction in adults with obesity over a 48-week period
PubMed Finan, B., Yang, B., Ottaway, N., Smiley, D.L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K.M., Fischer, K., Campbell, J.E., Sandoval, D., Seeley, R.J., Bleicher, K., Uhles, S., Riboulet, W., Funk, J., Hertel, C., Belli, S., Sebokova, E., Conde-Knape, K., Konkar, A., Drucker, D.J., Gelfanov, V., Pfluger, P.T., Mller, T.D., Perez-Tilve, D., DiMarchi, R.D., & Tschp, M.H
Unlike semaglutide, tirzepatide is a dual receptor agonist targeting both GLP1R and GIPR
You may upload your previous lab results into your portal or submit it to: [email protected] where someone from our team will upload it to your chart for your provider to review before your initial visit
Parthsarathy et al
Shipping and Storage Standard practices for handling retatrutide include temperature-controlled transport, tracked delivery, and refrigeration at 2C to 8C
